BLFS BioLife: Rasio rega marang prakiraan pendapatan
BioLife Solutions, Inc. (BLFS) is developing thawing automation and new cryopreservatives, driving growth within the biopharmaceutical sector. Integration into FDA regulations renders demand inelastic, granting the company significant pricing power. The shift in forward P/S confirms this potential, with the 61.10 mark characterizing this parameter. High business scalability is supported by equipment sales and a steady stream of orders for profitable consumables.
Rincian analitis perusahaan BioLife Solutions, Inc.
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Total Utang marang Modal BioLife Solutions, Inc.|BLFS - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas BioLife Solutions, Inc.|BLFS - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku BioLife|BLFS - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioLife Solutions|Indikator likuiditas cepet biolifesolutions.com
- indikator pendapatan resik lan kelipatan nilai:
BLFS - Bathi pungkasan|Proyeksi bathi mangsa ngarep BioLife Solutions, Inc.|BLFS - Periode bali modal bisnis|Rega marang bathi mangsa ngarep BioLife Corp|BLFS - Rasio P/E diaturake wutah|Pangali EV/EBITDA BioLife|BLFS - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan BioLife Solutions|BLFS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan biolifesolutions.com|BLFS - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep BioLife Solutions, Inc.
- data total pendapatan lan volume dodolan:
Analisis wiwitan perusahaan:BLFS (BioLife Solutions)
Analyzing the business of BioLife Solutions, Inc. (BLFS), the forward price-to-sales multiple chart reflects market expectations for the company's future scaling rates. This metric correlates current market capitalization with projected sales volume, measuring the premium for expansion potential within the biotechnology sector. The metric's sensitivity currently depends on the pace of venture capital investment in client developments, which directly impacts demand. The stabilization of customer inventories makes the asset reliable, despite the industry's temporary funding cycles.
Analisis pesaing BioLife Solutions, Inc.
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Qiagen NV (QGEN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|IONS - Rasio rega marang prakiraan pendapatan|RGEN: Rasio rega marang prakiraan pendapatan|RNA (Avidity Biosciences) - Multiplikator forward rega marang pendapatan|crisprtx.com (CRSP) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan WGS|RARE (Ultragenyx Pharmaceutical Inc.) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S BEAM|Rasio kapitalisasi marang dodolan sing dikarepake Sarepta Corp|Rasio rega marang prakiraan pendapatan Twist Bioscience TWST|10xgenomics.com (TXG) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NTLA - Rasio rega marang prakiraan pendapatan|STOK (Stoke Therapeutics Inc) - Kapitalisasi marang prakiraan pendapatan|Wave Life Sciences Corp (WVE) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan SION|PRME: Rega forward marang dodolan|Multiplikator Forward P/S TSHA|Rasio kapitalisasi marang dodolan sing dikarepake uniQure NV|Rasio rega marang prakiraan pendapatan MeiraGTx PLC MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc. - Multiplikator Forward P/S|ocugen.com (OCGN) - Multiplikator forward rega marang pendapatan|PACB (PacBio) - Multiplikator forward rega marang pendapatan|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|DSGN (Design Pharma) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan RCKT|Rasio rega marang prakiraan pendapatan 4D Molecular Therapeutics (FDMT)|Rasio rega marang prakiraan pendapatan LXEO (lexeotx.com)|Multiplikator Forward P/S KRRO (Korro Bio)|EDIT (Editas Medicine Inc) - Rega mangsa ngarep marang pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake ProQR Therapeutics N.V. PRQR|CDXS: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan SGMO|Rasio rega marang prakiraan pendapatan Nautilus Biotechnology, Inc.|Kapitalisasi marang prakiraan pendapatan MGX (Metagenomi Inc.)|Multiplikator Forward P/S DTIL|Multiplikator Forward P/S generationbio.com (GBIO)|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Exicure Inc. - Rasio rega marang prakiraan pendapatan|Celsion Corporation - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Phio Pharmaceuticals PHIO|mustangbio.com (MBIO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TransCode Therapeutics, Inc. (RNAZ)|Rasio rega marang prakiraan pendapatan Bionano Genomics Inc.|Rasio rega marang prakiraan pendapatan APDN|Multiplikator Forward P/S BLUE|Rasio kapitalisasi marang dodolan sing dikarepake immunoprecise.com|Multiplikator Forward P/S OMGA (Omega)|OMIC (Singular Genomics Corp) - Rega mangsa ngarep marang pendapatan|Regulus Therapeutics - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep syros.com|TBIO (Telesis Bio) - Multiplikator forward rega marang pendapatan|TRACON Pharmaceuticals Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Unity Bio
